Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial*-Reference-Cited by-同舟云学术

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial*

Published:2021-08-17 Issue:1 Volume:186 Page:30-39
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Thaçi D.¹^ORCID,Eyerich K.²^ORCID,Pinter A.³^ORCID,Sebastian M.⁴,Unnebrink K.⁵,Rubant S.⁵,Williams D. A.⁶,Weisenseel P.⁷

Affiliation:

1. Institute and Comprehensive Center for Inflammation Medicine University of Lübeck Lübeck Germany

2. Department of Dermatology and Allergy Technical University of Munich Munich Germany

3. Department of Dermatology, Venerology and Allergology University Hospital Frankfurt Frankfurt am Main Germany

4. Gemeinschaftspraxis für Dermatologie Mahlow Germany

5. AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany

6. AbbVie Inc. North Chicago IL USA

7. Dermatologikum Hamburg Germany

Funder

AbbVie

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20481

Reference50 articles.

1. Psoriasis

2. Pathogenesis and therapy of psoriasis

3. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

4. Current and future management of psoriasis

5. The global burden of psoriatic skin disease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study;JMIR Formative Research;2024-06-27

3. Deucravacitinib: is there still a place or a need for a new oral agent?;British Journal of Dermatology;2024-02-26

4. Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study (Preprint);2023-12-30

5. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15